S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α₂-Adrenoceptor Antagonist and Potential Antidepressant: I. A Mechanistic Characterization

Abstract

Although most antidepressants suppress serotonin (5-HT) and/or noradrenaline reuptake, blockade of 5-HT 2C receptors and ␣ 2 -adrenoceptors likewise enhances monoaminergic transmission. These sites are targeted by the urea derivative N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]-1,2-dihydro-3-H-benzo [e]indole-3-carboxamide (S32212). S32212 was devoid of affinity for monoamine reuptake sites, yet displayed pronounced affinity (pK i , 8.2) for constitutively active human 5-HT 2CINI (h5-HT 2CINI ) receptors, behaving as an inverse agonist in reducing basal G␣ q activation, [3 H]inositol-phosphate production, and the spontaneous association of h5-HT 2CINI -Renilla luciferase receptors with ␤-arrestin2-yellow fluorescent protein. Furthermore, upon 18-h pretreatment, S32212 enhanced the plasma membrane expression of h5-HT 2CINI receptors as visualized by confocal microscopy and quantified by enzyme-linked immunosorbent assay. Its actions were prevented by the neutral antagonist 6-chloro-5-methyl-N-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl]indoline-1-carboxamide (SB242,084), which also impeded the induction by long-term exposure to S32212 of otherwise absent Ca 2ϩ mobilization in mouse cortical neurones. In vivo, S32212 blunted the inhibitory influence of the 5-HT 2C agonist 2-(3-chlorobenzyloxy)-6-(1-piperazinyl)pyrazine (CP809,101) on ventrotegmental dopaminergic neurones. S32212 also blocked 5-HT-induced G␣ q and phospholipase C activation at the h5-HT 2A and, less potently, h5-HT 2B receptors and suppressed the discriminative stimulus properties of the 5-HT 2A agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane in rats. S32212 manifested marked affinity for human ␣ 2A -(pK i 7.2), ␣ 2B -(pK i 8.2), and ␣ 2C -(pK i 7.4) adrenoceptors, at which it abolished noradrenaline-induced recruitment of G␣ i3 , G␣ o , adenylyl cyclase, and extracellularregulated kinase1/2. Moreover, S32212 dose-dependently abolished the discriminative stimulus effects of the ␣ 2 -adrenoceptor agonist (S)-spiro[(1-oxa-2-amino-3-azacyclopent-2-ene)-4,2Ј-(1Ј, 2Ј,3Ј,4Ј-tetrahydronaphthalene)] (S18616). Finally, S32212 displayed negligible affinity for ␣ 1A -adrenoceptors, histamine H 1 receptors, and muscarinic M 1 receptors. In conclusion, S32212 behaves as an inverse agonist at h5-HT 2C receptors and as an antagonist at human ␣ 2 -adrenoceptors (and h5-HT 2A receptors). Its promising profile in preclinical models potentially relevant to the treatment of depression is described in J Pharmacol Exp Ther 340:765-780, 2012.

Antidepressant-Like Activity of YL-0919: A Novel Combined Selective Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist

“…The LANCE cAMP kit (PerkinElmer, Zaventem, Belgium) was used to determine cAMP concentrations according to the manufacturer's instruction [26], [27]. Briefly, the cells were grown to 80% confluence, harvested with versene, and washed once with HBSS.…”

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization

“…We first checked the specificity of the inhibitor S29434 for possible off-target activities (from the QR2 perspective). First, we assessed its activity in a series of standard assays designed to evaluate its behavior against a selection of receptors and enzymes [see, for example, Millan et al (2012)]. All tests were performed in duplicate, independently, at two concentrations: 100 nM and 10 mM.…”

Inverse Agonistic Action of 3-Iodothyronamine at the Human Trace Amine-Associated Receptor 5

“…Inverse agonism is a well-known mechanism of ligand action observed for constitutively active receptors [ 50 ] and has great therapeutic significance as a variety of clinically used drugs like β-blockers [ 51 ] and anti-allergic drugs targeting the histamine H1 receptor [ 52 ] act as inverse agonists [ 53 , 54 ]. The potential antidepressant S32212 showed inverse agonistic action at the serotonin receptor 2C in reducing basal IP 3 production mediated via G q/11 activation [ 55 ].…”